Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Targeting Intrinsic Immune Evasion Genes in Translocation Renal Cell Carcinoma to Improve GPNMB CAR-T Therapy
FY 2024-25
Summary
Translocation renal cell carcinoma (tRCC) is a rare and aggressive form of kidney cancer, primarily affecting adolescents, with no effective treatment options currently available. It is caused by genetic changes that affect certain proteins, leading to an increased abundance of a protein called glycoprotein non-metastatic melanoma protein B (GPNMB) on the surface of tRCC cells. Currently, GPNMB is being tested in clinical trials as a target for a promising cancer treatment called CAR-T cell therapy. However, cancers can develop resistance mechanisms against cancer therapies, including CAR-T cell therapy, making it challenging to eradicate the tumour. A major mechanism of resistance to CAR-T cell therapy is intrinsic immune evasion, which involves the tumour ability to evade detection and killing by the CAR-T cells, preventing them from destroying cancer cells. This research aims to identify genes in tRCC responsible for its ability to escape CAR-T cell killing and to develop a therapeutic that can be applied in the clinical setting. By using a powerful tool called CRISPR, precise cuts will be made at specific genes in the DNA of tRCC cells, rending these genes non-functional. This will enable the identification of genes that help tRCC resist GPNMB CAR-T cell therapy. Once immune evasion genes are identified, they will be tested in mice to determine whether disabling those genes could improve tRCC's sensitivity to CAR-T cell therapy. We will then establish a therapeutic to deliver CRISPR machinery directly into tRCC cells using lipid nanoparticles to target the immune evasion genes as an effective translational strategy. Overall, we intend to improve the effectiveness of GPNMB CAR-T cell therapy in treating tRCC to improve patient outcomes for this deadly disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530194
Name
Katsikaris Athanasia K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting Intrinsic Immune Evasion Genes in Translocation Renal Cell Carcinoma to Improve GPNMB CAR-T Therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunotherapy; Cancer Resistance Mechanisms; Car-T Cell Therapy; Genome Wide Crispr Knockout Screens; Humanized Mouse Models; Immune Evasion Gene Targeting; Lentiviral Transduction; Lipid Nanoparticle Delivery System; Translocation Renal Cell Carcinoma; Tumour Microenvironment
Abstract
Translocation renal cell carcinoma (tRCC) is a rare and aggressive form of kidney cancer, primarily affecting adolescents, with no effective treatment options currently available. It is caused by genetic changes that affect certain proteins, leading to an increased abundance of a protein called glycoprotein non-metastatic melanoma protein B (GPNMB) on the surface of tRCC cells. Currently, GPNMB is being tested in clinical trials as a target for a promising cancer treatment called CAR-T cell therapy. However, cancers can develop resistance mechanisms against cancer therapies, including CAR-T cell therapy, making it challenging to eradicate the tumour. A major mechanism of resistance to CAR-T cell therapy is intrinsic immune evasion, which involves the tumour ability to evade detection and killing by the CAR-T cells, preventing them from destroying cancer cells. This research aims to identify genes in tRCC responsible for its ability to escape CAR-T cell killing and to develop a therapeutic that can be applied in the clinical setting. By using a powerful tool called CRISPR, precise cuts will be made at specific genes in the DNA of tRCC cells, rending these genes non-functional. This will enable the identification of genes that help tRCC resist GPNMB CAR-T cell therapy. Once immune evasion genes are identified, they will be tested in mice to determine whether disabling those genes could improve tRCC's sensitivity to CAR-T cell therapy. We will then establish a therapeutic to deliver CRISPR machinery directly into tRCC cells using lipid nanoparticles to target the immune evasion genes as an effective translational strategy. Overall, we intend to improve the effectiveness of GPNMB CAR-T cell therapy in treating tRCC to improve patient outcomes for this deadly disease.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Katsikaris, Athanasia K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~